Market Place
Sourcing Support
Ultragenyx Pharma Investors Alerted Of Securities Class Action
06 Apr 2026 //
PHARMIWEB
Ultragenyx Pharma Investors With Losses Can Lead Class Action
14 Feb 2026 //
PHARMIWEB
Ultragenyx Unveils 2025 Financials And Corporate Progress
12 Feb 2026 //
GLOBENEWSWIRE
Ultragenyx Pharma Faces Securities Law Suit - Contact DJS Law
06 Feb 2026 //
PHARMIWEB
Investors With Losses In Ultragenyx Pharma (RARE) Can Lead Class
06 Feb 2026 //
PHARMIWEB
Ultragenyx Pharma Class Action Lawsuit Deadline: April 6, 2026 -
06 Feb 2026 //
PHARMIWEB
Rosen Law Urges Ultragenyx Shareholders to Contact on Suit
05 Feb 2026 //
PHARMIWEB
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
23 Jan 2026 //
GLOBENEWSWIRE
Ultragenyx Provides Financial, Business Updates at JPM Conference
12 Jan 2026 //
GLOBENEWSWIRE
Ultragenyx To Present At J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Ultragenyx Shares Plunge as Bone Disease Drug Fails
29 Dec 2025 //
REUTERS
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
19 Dec 2025 //
GLOBENEWSWIRE
Ultragenyx To Participate In Investor Conferences In December
24 Nov 2025 //
GLOBENEWSWIRE
Ultragenyx Unveils Q3 2025 Financials & Corporate Update
04 Nov 2025 //
GLOBENEWSWIRE
Ultragenyx Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
24 Oct 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Per Nasdaq LR 5635(C)(4)
03 Oct 2025 //
GLOBENEWSWIRE
Ultragenyx Appoints Eric Olson As Chief Business Officer
30 Sep 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
19 Sep 2025 //
GLOBENEWSWIRE
Ultragenyx to Participate at Investor Conferences in September
29 Aug 2025 //
GLOBENEWSWIRE
Ultragenyx Announces Inducement Grant Under Nasdaq 5635(c)(4)
21 Aug 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Q2 2025 Financial Results and Corporate Update
05 Aug 2025 //
GLOBENEWSWIRE
Ultragenyx`s Q2 2025 Financial Results and Corporate Update Call
30 Jul 2025 //
GLOBENEWSWIRE
Ultragenyx grants inducement under Nasdaq Listing Rule 5635(c)(4)
18 Jul 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
20 Jun 2025 //
GLOBENEWSWIRE
Ultragenyx to Attend Goldman Sachs Global Healthcare Conference
03 Jun 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
20 May 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Q1 2025 Financial Results and Update
06 May 2025 //
GLOBENEWSWIRE
Ultragenyx to Host Conference Call for Q1 2025 Financial Results
30 Apr 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
22 Apr 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
19 Mar 2025 //
GLOBENEWSWIRE
Ultragenyx to Participate at Investor Conferences in March
24 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
19 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Q4 & Full Year 2024 Financial Results & Update
13 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx to Host Call for Q4 & Full-Year 2024 Financial Results
06 Feb 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq L R 5635(c)(4)
17 Jan 2025 //
GLOBENEWSWIRE
Ultragenyx Reports 2024 Revenue, 2025 Guidance & Pipeline Updates
12 Jan 2025 //
GLOBENEWSWIRE
Ultragenyx to Present at the 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
20 Dec 2024 //
GLOBENEWSWIRE
Ultragenyx to Participate in Investor Conferences in December
26 Nov 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635
20 Nov 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Q3 2024 Financial Results & Corporate Update
05 Nov 2024 //
GLOBENEWSWIRE
Ultragenyx to Host Call for Q3 2024 Results and Update
29 Oct 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Rule 5635(c)(4).
18 Oct 2024 //
GLOBENEWSWIRE
Ultragenyx to Participate in Investor Conferences in September
29 Aug 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 Aug 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
01 Aug 2024 //
GLOBENEWSWIRE
Ultragenyx To Host Q2 2024 Results And Update Call
25 Jul 2024 //
GLOBENEWSWIRE
Ultragenyx To Update On GTX-102 For Angelman Syndrome At ASF Event
24 Jul 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 Jul 2024 //
GLOBENEWSWIRE
Ultragenyx Completes FDA End-Of-Phase 2 Meeting For GTX-102
17 Jul 2024 //
GLOBENEWSWIRE
Ultragenyx Prices Public Offering Of Common Stock, Pre-Funded Warrants
13 Jun 2024 //
GLOBENEWSWIRE
Ultragenyx, Mereo`s brittle bone drug sustains fracture rate cut
13 Jun 2024 //
FIERCE BIOTECH
Ultragenyx & Mereo BioPharma Announce New Pha2 Data from Phase 2/3 Orbit Study
11 Jun 2024 //
GLOBENEWSWIRE
Ultragenyx: Participating At Goldman Sachs Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
Ultragenyx Positive Phase 3 Results For DTX401 In Glycogen Storage Disease
30 May 2024 //
GLOBENEWSWIRE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 May 2024 //
GLOBENEWSWIRE
Ultragenyx to Participate at Bank of America`s 2024 Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
02 May 2024 //
GLOBENEWSWIRE
Ultragenyx Issues 2023 Corporate Responsibility Report
30 Apr 2024 //
GLOBENEWSWIRE
Ultragenyx Hosts Q1 2024 Call and Corporate Update
25 Apr 2024 //
GLOBENEWSWIRE
